Expression and Prognostic Role of MEKK3 and pERK in Patients with Renal Clear Cell Carcinoma |
Chen, Qi
(Department of Clinical Laboratory, Taizhou Central Hospital)
Lu, Hong-sheng (Department of Pathology, Taizhou Central Hospital) Gan, Mei-fu (Department of Pathology, Taizhou Hospital) Chen, Lan-xi (Department of Pathology, Taizhou Central Hospital) He, Kai (Department of Pathology, Taizhou Central Hospital) Fan, Guang-min (Department of Pathology, Taizhou Central Hospital) Cao, Xue-quan (Department of Pathology, Taizhou Central Hospital) |
1 | Cao X, Lu H, Zhang L, et al (2014). MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac J Cancer Prev, 15, 5271-76. DOI |
2 | Christophe F, Sylvain M (2010). From basic research to clinical development of MEK 1/2 inhibitors for cancer therapy. J Hematol Oncol, 3, 3-8. DOI |
3 | Chen L, Shi Y, Jiang CY, et al (2011). Expression and prog- nostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. EJSO, 37, 513-20 DOI |
4 | Cindy Neuzillet, Annemilai Tijeras-Raballand, Louis de Mestier, et al (2014). MEK in cancer and cancer therapy. Pharmacol Ther, 141, 160-71. DOI |
5 | Craig EA, Stevens MV, Vaillancourt RR, et al (2008). MAP3Ks as central regulators of cell fate during development. Developmental Dynamics, 237, 3102-14. DOI ScienceOn |
6 | Escudier B, Eisen T, Stadler WM, et a1 (2007). SorMenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, l25-34. DOI |
7 | Hanahan, D, Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74. DOI |
8 | Kamal S, Sherene L, Evandro de Azambuja, et al (2013). Targeting the PI3K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev, 39, 935-46. DOI |
9 | Lee HE, Park DJ, Kim WH, et a1 (2011). High FOXP3 regulatory t-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br J Cancer, 34, 413-19. |
10 | Lu H, Cao X, Zhang H, et al (2014). Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumor Biol, 35, 9807-13. DOI |
11 | Lu H, Gan M, Zhang G, et al (2010). Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Eur J Gynaecol Oncol, 6, 662-66. |
12 | McCubrey JA, Steelman LS, Chappell WH, et al (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773, 1263-84. DOI |
13 | Shinohara H, Yamasaki S, Maeda S, et a1 (2009). Regulation of NF- dependent T cell activation and development by MEKK3. Int Immunol, 21, 393-401 DOI |
14 | Wang G, Liu G, Liu Y, et a1 (2012). FOXP3 expression in esophageal cancer cells is associated with poor prognosis in esophageal cancer. Hepatogastroenterol, 59, 2186-91. |
15 | Wang X, Chang X, Su B, et a1 (2009). MEKK3 is essential for lymphopenia induced T cell proliferation and survival. J Immunol, 6, 3597-608. |
16 | Yoshimura K, Uemura H (2013). Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. Int J Urol, 20, 744-55. DOI |
17 | Zeng C, Yao Y, Jie W, et al (2013). Up-regulation of Foxp3 participates in progression of cervical cancer. Cancer Immunol Immunother, 3, 481-7. |
18 | Young A, Lou D, McCormick F (2013). Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov, 1, 112-23. |